Silencing gene expression to cure complex diseases

Many people think of new medicines as bullets, and in the pharmaceutical industry, frequently used terms like “targets” and “hits” reinforce that idea. Immuneering co-founder and CEO Ben Zeskind ’03, PhD ’06 prefers a different analogy. His company, which specializes in bioinformatics and computational biology, sees many effective drugs more like noise-cancelling headphones. Rather than […]